With Insmed Inc.’s phase III Convert trial expected to read out any day, onlookers are busying themselves with guesswork about success for amikacin liposome inhalation suspension, formerly called Arikayce but now known by the acronym ALIS, in non-tuberculous mycobacterium (NTM) infection.